Health coverage where every claim has a source
US Health Digest reports on women's health, weight-loss medicine and telehealth in America — with every statistic linked to the trial, regulator or dataset it comes from. No source, no sentence.
Start with the GLP-1 FAQ →Featured coverage
Storm Season and Refrigerated GLP-1s: What the Labels Allow When the Power Goes Out
Indiana's floods left 150,000+ without power. The exact room-temperature windows in the FDA labels for Wegovy, Ozempic, Zepbound and Mounjaro — and what to do after a flood.
How to Spot a Fake Weight-Loss Testimonial: The FTC’s Own Rulebook, Applied
Seven claims the FTC says are always false, the 2024 rule that bans AI-generated reviews, and a checklist for reading any GLP-1 ad.
GHK-Cu, the Copper Peptide in Your Serum: What the Evidence Actually Shows
Five decades of lab research, a marketing machine — and one peer-reviewed randomized facial trial, with 13 completers, that came back null.
GLP-1 Weight-Loss Medication for Women: Every Question, Answered With Sources
Costs, results, side effects, safety and the compounding controversy — the complete evidence-backed FAQ.
Compounded vs Branded GLP-1s in 2026: What the FDA Actually Says
The regulatory crackdown explained — what's legal, what's not, and what it means if you're taking a compounded version.
Semaglutide for Women: What the Clinical Trials Actually Show
The real numbers from the pivotal trials — average loss, timelines, and side effects — without the marketing gloss.
Best GLP-1 Telehealth Programs for Women (2026 Comparison)
Seven real programs compared on price, medication type and oversight — including what the budget options don't advertise.
GLP-1 Statistics 2026: Every Number, Sourced
Usage, trial results, side effects, regain and the crackdown — the reference numbers in one place.
What GLP-1 Treatment Really Costs Without Insurance
Why per-month prices mislead, what quotes actually include, and the real math over a treatment horizon.
Health decisions happen in real life — between school runs, work and the dog's walk. That's why we skip the miracle framing and give you the trial data, the real costs and the regulatory facts, so the decision you make fits the life you actually have. Start with the FAQ or the numbers.
The World Cup Is Over. The Walking Isn't.
What a month of soccer fever says about how America moves — and what actually sticks after the final whistle.
Latest coverage
Elecoglipron (AZD5004): What the VISTA and SOLSTICE Phase 2 Trials Actually Showed, and When Phase 3 Reports
AstraZeneca's oral small-molecule GLP-1 elecoglipron reported 11.8% weight loss at 36 weeks in VISTA. That is a secondary endpoint under the efficacy estimand, not a phase 3 primary result. The co-primary was 10.5% at 26 weeks. The drug is not approved, not available, and its first phase 3 obesity readout is not due until July 2028.
Sermorelin: The FDA Record, the Growth-Hormone Evidence, and Where It Legally Sits Now
Sermorelin acetate was a real FDA-approved drug - Geref and Geref Diagnostic, approved 1990 and 1997, withdrawn effective June 18, 2009. FDA later determined the withdrawal was not for reasons of safety or effectiveness. What that determination governs, where sermorelin sits on FDA's compounding lists, and what the adult trials actually measured.
Calibrate Review 2026: The $199-a-Month Metabolic Reset, Priced Against the Drug-Only Alternatives
Calibrate's own pricing page says $199 a month with a three-month commitment, read September 2, 2026 - not the $1,500-$1,999 a year that 2026 review sites still repeat. What the fee includes, what the Results Money Back Promise actually requires, how it compares with Ro, Noom Med, Found, Hers and Mochi on a single axis set, and whether any randomised trial has ever tested year-long coaching added to a GLP-1.
Mounjaro's New Cardiovascular Indication: What SURPASS-CVOT Showed, What It Did Not, and Why It Stops at Mounjaro
On August 28, 2026 the FDA approved Mounjaro to lower major adverse cardiovascular event risk in adults with type 2 diabetes at high risk. The trial behind it tested non-inferiority against Trulicity, not superiority against placebo, and the confidence interval crosses 1. We read the NEJM paper, the Lilly release and five current DailyMed labels to establish exactly who the indication covers, and whether it reaches Zepbound.
The Dietary Guidelines Deleted the One-Drink-a-Day Limit for Women: What the Two Documents Actually Say
The Dietary Guidelines for Americans, 2025-2030 contain no numeric alcohol limits at all. We downloaded the PDF, searched the full text for every phrasing of the old rule, and set the two bullets that remain beside the 605 words the 2020-2025 edition gave the subject. CDC still publishes the old numbers today.
Do Women Lose More Weight on GLP-1s Than Men? What the Sex-Difference Evidence Actually Shows
A 2026 JAMA Internal Medicine meta-analysis found GLP-1 weight loss was consistent across age, race, ethnicity, baseline BMI and A1c — with sex the one exception: 10.9% for women against 6.8% for men. The percentages are real. What they mean depends entirely on a denominator almost nobody prints.
"Research Use Only": What That Label Actually Means for Peptides in the US
"Research use only" is a labelling status borrowed from a device regulation - 21 CFR 809.10(c)(2)(i) - and it appears exactly once in FDA's rules, for in vitro diagnostics. It is not an FDA approval category and it does not make a peptide legal to sell for human use. The five legal boxes a peptide can occupy, what FDA enforcement has actually looked like, and what the documented federal record says about the claim that peptides became 'legal again' in 2026.
GLP-1s and Bone Density: What Was Measured, What Is Inferred, and What Postmenopausal Women Should Ask For
Neither STEP 1 nor SURMOUNT-1 measured bone mineral density — their DXA sub-studies were built to show the lost weight was fat. What the one randomised bone trial found, what the Wegovy label reports about fractures in women, and why weight loss itself is the leading explanation.
People on GLP-1s Moved Less, Not More — What the ENDO 2026 Poster Actually Says
A conference poster presented at ENDO 2026 reported that daily steps fell after adults with obesity started a GLP-1. We read the primary abstract. Here is what it measured, the three things it never measured, and how it sits beside what the pivotal trials actually prescribed.
Mochi Health Review 2026: What the Program Actually Costs, and What You Are Buying
A sourced review of Mochi Health: the corporate and medical-group structure named in its own terms, what its "board certified obesity medicine" claim does and does not mean, every published price with an as-of date, the compounded-GLP-1 question against FDA's 2026 record, and an explicit Hers vs Mochi comparison.
Alcohol on a GLP-1: What the Labels Say, What the Trials Found, and What Is Still Anecdote
We searched the full text of twelve current US GLP-1 labels for the word alcohol. On the weight-management products every hit is an alcohol swab, an excipient or the old name for fatty liver disease. The two labels that do name drinking are the ones that also contain insulin. Plus the three randomised trials, the observational data, and the reports that are still only reports.
Every Legitimate Self-Pay Route to a GLP-1 in the US in 2026, Priced Side by Side
A route-by-route map of how to buy a GLP-1 with your own money in 2026: LillyDirect, NovoCare Pharmacy, TrumpRx.gov, the oral tier, retail list price, generic liraglutide, telehealth memberships and copay cards. Every figure carries its source document, its as-of date and its price type.
Am I Eligible for a GLP-1? What Each Label Actually Says — and What Programs Add On Top
The FDA-approved labels for Wegovy, Zepbound, Foundayo and Saxenda set the eligibility floor for GLP-1 weight-management prescribing. What the current DailyMed labels say word-for-word about BMI, comorbidities, adolescents and contraindications — and how Medicare, state Medicaid and employer programs layer their own criteria on top.
Meta's Teen Settlement Has a Body-Image Clause. It Is the Least Measurable Part of the Document.
The consent judgment entered August 26, 2026 in MDL 3047 defines "Sensitive Aggregate Content" — weight, physique and body-idealization posts — but attaches no number to it, while the time limits get exact ones. What the filing says, what the headline figures count, and what the evidence supports.
Getting a GLP-1 Covered for Sleep Apnea: What SURMOUNT-OSA Showed and What Plans Require
Zepbound (tirzepatide) is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. What the label actually says, what the SURMOUNT-OSA trials measured, and what named health plans and Medicare require before they will pay - sourced to DailyMed, PubMed, payers' own policy documents and the Federal Register.
GLP-1s, Mood and Antidepressants: What the Labels Say Now, and What the Suicidality Evidence Actually Shows
In January 2026 the FDA asked manufacturers to remove the suicidal behavior and ideation warning from GLP-1 weight-management labels, and by February 2026 it was gone from Wegovy, Zepbound and Saxenda. What the labels used to say, what the pharmacovigilance and cohort evidence really supports, and what it means for a woman already taking an antidepressant.
"Ozempic Face": What Facial Volume Loss on GLP-1s Actually Is, and What the Evidence Shows
"Ozempic face" is a media term, not a diagnosis: it appears in no FDA label and no ICD-10-CM code. One retrospective imaging study of 20 patients has quantified midface volume loss on GLP-1s; no registrational trial measured the face at all. What the published studies actually measured, what the aesthetics industry is selling against it, and what is genuinely supported for someone worried about it.
TB-500 and Thymosin Beta-4: The Evidence and the Legal Status, Audited
TB-500 is sold as a healing and recovery peptide. FDA's own May 2026 review found no published study in which it was administered to a human, and concluded the criteria weigh against allowing it in compounding - three weeks before an advisory panel voted the other way. What the record actually contains, and how TB-500 differs from the two other thymosins it gets confused with.
GLP-1s and the Pill: Which Labels Carry an Oral-Contraceptive Instruction
The Zepbound, Mounjaro and Foundayo labels each carry an instruction about oral hormonal contraceptives tied to delayed gastric emptying. The Wegovy, Ozempic and Rybelsus labels do not. Exact wording, label dates and DailyMed links for every product.
Hair Loss on GLP-1s: What the 2026 Evidence Actually Shows
A July 2026 BMJ target trial emulation found that, among adults with type 2 diabetes, GLP-1 initiators had more clinically recorded hair loss than users of two comparator diabetes drugs, with a low absolute risk. What the study can and cannot show, what the Wegovy and Zepbound labels report by sex, and why rapid weight loss is the leading competing explanation.
CagriSema: What the REDEFINE Trials Showed, and What an FDA Decision Would Change
CagriSema (cagrilintide plus semaglutide) is not approved in the US. A New Drug Application was submitted in December 2025 and the company expects a decision in late 2026. What REDEFINE 1, 2 and 4 actually reported, with each figure tied to its estimand.
The US Open Put a Number on Dangerous Heat. Public Health Guidance Mostly Won't.
Tennis measures heat stress on court every 30 minutes and acts at a written threshold. CDC, the National Weather Service and OSHA say something different to everyone else. What the numbers actually mean.
GLP-1s in Perimenopause and Menopause: What the Evidence Supports, and What It Does Not
Women aged 50 to 64 report the highest GLP-1 use of any US group, yet the pivotal obesity trial registries record nothing about menopausal status. What the hormone-therapy cohorts actually found, what menopause changes versus what ageing changes, and the questions worth asking.
Hers Weight Loss: What the Program Actually Costs, and What You Are Buying (2026)
A sourced breakdown of the Hers weight loss program: the membership fee and the medication price are separate subscriptions, what each covers, whether the medicine is branded or compounded, how the clinical review works, and how the arithmetic compares with Ro, Noom Med and Found as of August 2026.
Traveling With a GLP-1 Over Labor Day Weekend: What the Rules Actually Say
TSA's own pages say medically necessary liquids over 3.4 oz and the gel packs keeping a pen cold are on TSA's permitted lists when you declare them, though the officer makes the final call, and that TSA does not require prescription bottles — but state labeling laws may. What the current DailyMed labels say about cold storage, missed doses and changing your dose day, and what they do not say about time zones.
The GLP-1 Eye-Injury Lawsuits: What MDL 3163 Actually Is
Federal NAION vision-loss cases against GLP-1 makers were consolidated into MDL No. 3163 before Judge Karen S. Marston in December 2025; 200 actions were pending as of the JPML's August 3, 2026 report. What an MDL is, how it differs from the older MDL 3094, and what a patient should do.
GLP-1 Drugs and Fatty Liver Disease: What Is Actually FDA-Approved for MASH
Wegovy (semaglutide 2.4 mg) holds an accelerated approval for noncirrhotic MASH with F2-F3 fibrosis, granted August 15, 2025 on the ESSENCE trial. Zepbound does not. What the pivotal trials showed, why accelerated approval matters, and what the evidence says for women in midlife.
Melanotan II: What the Evidence and the Law Actually Say About the "Tanning Injection"
Melanotan II is sold online as a tanning injection and nasal spray. No FDA-approved drug contains it, the published human tanning evidence is one 1996 pilot study in three men, and the safety record is a stack of case reports. What the peer-reviewed literature and the regulators actually say - and how melanotan II differs from the two melanocortin peptides FDA really did approve.
Ro vs Noom Med vs Found: The Branded-Pathway GLP-1 Telehealth Head-to-Head for Women (2026)
Ro, Noom Med, and Found compared for women choosing a branded-only GLP-1 telehealth program: program fees, medication cost handling, NovoCare and LillyDirect routing, prescribers, insurance help, and cancellation terms, verified on each company's own pages as of August 2026.
Back to School 2026: How Families Actually Reset Health Routines — and Two Ways This Season Is Different
Tens of millions of US kids are heading back to class over the next few weeks. The evidence-backed way to reset sleep, meals, and movement — plus what's changed on the school lunch tray, and how GLP-1 medications now touch this season in two very different ways.
US Peptide Market Statistics 2026: Every Number, Sourced
The key US peptide market numbers in one place: GLP-1 revenue from Novo Nordisk and Eli Lilly's own reports, usage polls, research-firm market estimates with their spread, and the FDA enforcement record — each figure linked to its primary source.
What Happens at a GLP-1 "Medical Review" — and What a Rubber-Stamp Intake Looks Like
What a legitimate prescriber evaluation for Wegovy or Zepbound must screen for — thyroid cancer history, pregnancy, pancreatitis, drug interactions, BMI eligibility — and the marks of an intake built to sell rather than evaluate, tied to FDA and FSMB primary sources.
Aleniglipron Enters Phase 3: What the Next GLP-1 Pill Contender Has Actually Shown
Structure Therapeutics has dosed the first patients in its phase 3 ACCOMPLISH program for aleniglipron, a once-daily oral GLP-1. In the 230-person phase 2b ACCESS trial, the pill cut body weight by a placebo-adjusted 8.2% to 11.3% at 36 weeks. Why those numbers deserve a discount, and how the pill sits against oral Wegovy and Foundayo.
PT-141 / Bremelanotide: The FDA-Approved Women's Peptide vs. the Gray Market
Bremelanotide (Vyleesi) is the one peptide sold to women that is actually an FDA-approved drug — for hypoactive sexual desire disorder in premenopausal women. The trial effects are real but modest, the nausea rate is 40%, and the 'PT-141' vials sold online are not the approved product. Every claim verified against FDA records and PubMed.
Switching From Wegovy or Zepbound to a Daily Pill: What the First Trial Actually Shows
In the ATTAIN-MAINTAIN trial, adults who switched from tirzepatide or semaglutide injections to the daily pill orforglipron (Foundayo) kept 74.7% and 79.3% of their prior weight loss at one year, versus 49.2% and 37.6% on placebo, all under the trial's primary modified treatment-regimen estimand. What the trial shows — and what it cannot.
Wednesday's Solar Eclipse: How to Watch the Partial Phase Without Damaging Your Eyes
On August 12, 2026, a total solar eclipse crosses Greenland, Iceland, and Spain — and much of the US, from Alaska to North Carolina, sees a partial eclipse around midday. In a partial eclipse there is never a safe moment to look without protection. Here is how to watch it safely, per NASA, the AAO, and the AAS.
Peptide Safety in 2026: Legal Channels, Gray-Market Purity, and How to Read a Certificate of Analysis
Every peptide sold in the US sits in one of three legal channels: FDA-approved drug, 503A/503B compounding under the bulks-list rules, or a gray-market 'research use only' vial. What published testing has found in that gray market, what a certificate of analysis can and cannot prove, and the red flags — all from primary documents.
The FDA's National Priority Voucher: What It Is — and What It Is Not
Nine products, including Wegovy HD and Foundayo (orforglipron), have been approved under the FDA's Commissioner's National Priority Voucher pilot. The voucher compresses review time — a 1-2 month target against 6+ months — without lowering the evidence bar, and it is not Accelerated Approval.
CJC-1295 and Ipamorelin: What the Evidence Actually Shows
Anti-aging clinics sell CJC-1295 and ipamorelin as growth hormone boosters. The entire human evidence base is a handful of small studies from 1999-2014, none testing the marketed uses — and ipamorelin failed its only trial in patients. The evidence and legal status, verified against primary sources.
Wegovy HD (Semaglutide 7.2 mg): What the Higher Dose Actually Buys
The FDA approved Wegovy HD, semaglutide 7.2 mg, on March 19, 2026. What STEP UP found under each estimand, the 3.1-point gain over 2.4 mg, the dysaesthesia signal, and the price.
GLP-1 "Microdosing": What the Evidence Shows, and Why the Word Is Doing Legal Work
Microdosing means taking semaglutide or tirzepatide below the approved label's maintenance doses, usually compounded. We searched PubMed on August 6, 2026 and could locate no randomized trial of these doses for weight management in adults without diabetes. What the labels specify, what the dose-response data show, and where the compounding law sits.
Collagen Peptides: What the Randomised Trials Actually Show for Skin, Joints, Hair and Nails
Collagen is the one corner of the peptide market with a large randomised human evidence base — and the honest reading gives a different answer for each of the four things it is sold for. The meta-analyses, the funding problem, the joint pool that mixes two different products, and the single hair trial that exists.
Retatrutide's Phase 3 Numbers Are Out. The Peer-Reviewed Papers Are Not.
Lilly has now reported topline results from three Phase 3 retatrutide obesity trials — TRIUMPH-1, -2 and -3. What each reported, under which estimand, what the safety data show, and why the drug sold online as a "research peptide" is not the same thing.
What Peptide Therapy Actually Costs in 2026: Clinics, Telehealth and the Gray Market
A sourced price table for peptide therapy in August 2026 — manufacturer direct-pay prices for approved GLP-1s, published clinic prices for compounded peptides, and what a "research use only" vial lists for. Every number is attributed to the seller's own page, with the date observed.
Ozempic Is a Peptide: What That Shared Chemistry Actually Explains
Semaglutide and tirzepatide are peptides — the same chemical class as the vials sold by research-peptide vendors. That single fact explains why these drugs are injected, why they need refrigeration, why an identical amino-acid sequence is not an identical product, and why one FDA compounding fight governs both markets.
The Third Wave: FDA Sent Another Round of Telehealth Warning Letters in June — With No Press Release We Could Find
FDA has run three rounds of enforcement against telehealth companies marketing compounded GLP-1s since September 2025. For the June 2026 round we could locate no press release. What the letters allege, and the five marketing practices FDA says are improper.
GLP-1 Drugs and PCOS: What the Evidence Actually Shows
Pooled randomized-trial evidence on GLP-1s for PCOS: consistent effects on weight, BMI and waist, a negative finding on insulin resistance, and thin reproductive data.
Do GLP-1 Drugs Make You Lose Muscle? What the Trials Actually Measured
Lean body mass does fall on GLP-1 drugs — a mean difference of -1.51 kg versus comparator, with lean tissue about 28% of weight lost across pooled GLP-1 and SGLT2 trials. But lean mass is not muscle, the evidence stops at October 2022, and almost nobody has measured strength.
GLP-1 Medication in a Record-Hot Summer: A Documented Mechanism, an Unmeasured Interaction
The Wegovy label documents dehydration and kidney injury after GI side effects. CDC's heat guidance names no GLP-1 drug. What that overlap does and does not mean.
What Are Peptides? One Word, Three Completely Different Markets
A peptide is a short chain of amino acids — a chemistry word, not a category of medicine. The same word now covers FDA-approved drugs, supplement-aisle collagen, and gray-market vials labeled 'not for human consumption'. Here is the map, plus the July 2026 FDA compounding fight.
BPC-157: What the Human Evidence Shows and What the FDA Advisory Vote Actually Changed
An FDA advisory committee voted 8-6 on July 23, 2026 to recommend BPC-157 for the 503A compounding list. FDA's own reviewers recommended against it. What the human evidence is, what the vote does and does not do, and why BPC-157 is still not an approved drug.
The Oral GLP-1 Race: What the First Pill-vs-Pill Head-to-Head Trial Actually Showed
ACHIEVE-3 pitted orforglipron against oral semaglutide and orforglipron won on A1c and weight — but it was a type 2 diabetes trial, and orforglipron had more GI side effects and twice the discontinuation rate. What that does and does not mean for weight loss.
Medicare GLP-1 Bridge: Who Qualifies and How to Use the $50/Month Program (2026)
The Medicare GLP-1 Bridge went live July 1, 2026. Who qualifies, which drugs are covered, how the prescription and prior authorization actually work, and what the $50 copay does and doesn't count toward — sourced to medicare.gov, CMS, and KFF.
GLP-1s Are Replacing Surgery for Teens With Obesity: What Families Should Know
A JAMA Pediatrics study of 204,000+ patients aged 13–25 finds GLP-1-only treatment rose to 96.1% while bariatric surgery fell to 3.7%. The adolescent evidence, the unknowns, and what to ask a pediatrician.
US Obesity Rate Is Falling as GLP-1 Use Hits 11%: What Gallup's Numbers Show
Gallup finds US adult obesity at 36.4% in 2026, down from a 39.9% peak, while 1 in 9 adults now take a GLP-1. What the survey shows — and what it can't.
GLP-1 Weight-Loss Medication for Women Over 40: What the Evidence Shows
What GLP-1 trials do and don't establish for women over 40: midlife body composition, lean mass, bone health, maintenance after stopping, and open questions.
How to Appeal a GLP-1 Weight-Loss Drug Denial: Step-by-Step (2026)
Denied GLP-1 coverage? Step-by-step guide to internal appeals, external review, and Medicare Part D appeals — deadlines sourced to healthcare.gov and CMS.
Semaglutide and Rare Vision Loss: What the NAION Evidence Shows
A 2026 meta-analysis and Europe's 2025 label decision tie semaglutide to a very rare optic-nerve condition. The absolute risk in plain numbers, and what to do.
The GLP-1 Pill Era Is Here: Oral Wegovy vs Foundayo (Orforglipron) — and What Online 'Oral Kits' Are Not (2026)
Two FDA-approved GLP-1 pills now exist: oral Wegovy (semaglutide 25 mg) and Foundayo (orforglipron). What the OASIS 4 and ATTAIN-1 trials found, how the pills compare with injections, and why the 'oral semaglutide kits' sold online are neither.
Does Insurance Cover GLP-1 Weight-Loss Medication in 2026? Medicare's $50 Bridge, Medicaid, and Employer Plans
Medicare's new $50/month GLP-1 Bridge program started July 1, 2026. What it covers, how Medicaid varies by state, what employer plans actually do, and a step-by-step checklist to find out where you stand.
FDA Moves to Make the Compounded GLP-1 Ban Permanent: Comment Period Closed, No Final Rule Yet
The FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from large-scale compounding. The comment period, extended once, closed July 30, 2026, and no final rule has issued. What's proposed vs. final — and what to do if you're on a compounded program.
Wegovy vs Zepbound for Women: The Trial-by-Trial Comparison (2026)
Semaglutide (Wegovy) vs tirzepatide (Zepbound) for women: what the STEP 1, SURMOUNT-1, and head-to-head SURMOUNT-5 trials actually found on weight loss, side effects, and cost trade-offs.
How GLP-1 Telehealth Actually Works: From Intake to First Dose (and the Red Flags at Each Step)
The six steps of a GLP-1 telehealth program — intake, clinician review, prescription, pharmacy shipping, dose escalation, and renewals — with the legitimate version and the red-flag version of each.
GLP-1 Side Effects in Women: What the Trials Report (2026)
What the STEP 1 and SURMOUNT-1 trials report about GLP-1 side effects — the GI-dominant profile, the 4.5% discontinuation figure, the serious risks prescribers screen for, and when to call a clinician.
What Happens When You Stop Taking a GLP-1 (And What Maintenance Actually Looks Like)
SURMOUNT-4 withdrawal evidence on weight regain after stopping GLP-1 medication, new real-world data on what 7,938 patients actually did after discontinuing, and the maintenance options to discuss with a clinician.
GLP-1s, Pregnancy and Fertility: What Women Planning a Family Need to Know (2026)
GLP-1 weight-loss medications are not for use in pregnancy. What that means if you are planning a family: stopping in advance, fertility effects to discuss with a clinician, contraception conversations, and what to do if you become pregnant on the medication.
GLP-1 and Weight-Loss Medication Terms, Explained in Plain English (2026 Glossary)
Semaglutide, tirzepatide, compounded, 503A/503B, titration, telehealth intake — the weight-loss medication vocabulary defined precisely, with sources.
RxFemale Review 2026: Is the Budget GLP-1 Telehealth Program Legit?
An honest RxFemale review — what the $129.99 compounded GLP-1 program includes, where its marketing overreaches, the regulatory risk, and who it's a rational choice for.
Eating on a GLP-1: What Changes, What to Prioritize, and the Small-Meals Reality
How appetite suppression reshapes eating on GLP-1 medication — what the Wegovy label actually states about appetite, gastric emptying and GI adverse reactions, what MedlinePlus defines and does not define, and where the documents run out and clinical convention takes over.
Protein-First Eating on a GLP-1: Why It Matters and How to Do It Without Influencer Math
Why protein becomes the priority when a GLP-1 shrinks your appetite, what protein-first actually means at the plate, realistic sources for smaller appetites, and why we won't give you a universal grams number.
Why trust this site?
Because you shouldn't have to trust us — you can check. Our editorial policy is simple: every factual claim links to a primary source (a peer-reviewed trial, a regulator, or a named dataset), we never publish invented testimonials, and pages that earn us a commission say so at the top. Read how we work on our About page.